2021分子ESGO/ESTRO/ESP风险分组在子宫内膜癌中的实施
该研究对604例子宫内膜癌患者应用2021年ESGO/ESTRO/ESP分子风险分组,并与2016年临床病理分组比较。2021分子分组显示组间总生存差异显著;39例(39/594,7%)风险组别发生改变,仅由P53abn或POLEmut分子标志物导致。在资源有限时,可显著减少所需分子检测数量。
要点
- 2021分子风险分组可行,且组间总生存差异显著。
- 39/594例(7%)风险组别因P53abn或POLEmut发生改变。
- 资源有限时可选择性检测:TP53 IHC 433例(72.9%),MMR IHC 46例(7.7%),POLE测序286例(48.1%)。
核心结论
- 2021分子风险分组可行,且显示组间总生存差异显著。
- 应用TP53和MMR免疫组化及POLE测序仅在部分病例需要,可使相当数量患者风险组别上调或下调。
研究设计与样本
- 对604例子宫内膜癌患者,用组织芯片进行TP53和MMR蛋白免疫组化及POLE突变Sanger测序进行分子分型。
- 结合临床病理数据,分别按2021分子/临床病理参数和2016临床病理系统进行风险分组并比较。
主要发现
- 2021分子标志物应用后,Kaplan-Meier曲线显示组间总生存差异显著。
- 按2021指南分子分型,共39例(39/594,7%)风险组别较2016分类系统发生改变,且改变仅由P53abn或POLEmut分子标志物导致。
关键数值与推荐
- 为确保2021分子风险分类正确,并非所有子宫内膜癌患者均需分子诊断:433例(72.9%)需TP53免疫组化分析,仅46例(7.7%)需MMR免疫组化,286例(48.1%)需POLE测序反应。
临床怎么用
- 资源有限时可选择性进行TP53免疫组化、MMR免疫组化和POLE测序,以显著减少实施分类所需分析数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In 2021, a joint ESGO/ESTRO/ESP committee updated their evidence-based guidelines for endometrial cancer, recommending a new risk grouping incorporating both clinicopathologic and molecular parameters. We applied the new risk grouping and compared the results to those of the prior 2016 clinicopathologic system. MATERIALS AND METHODS: We classified molecularly a cohort of 604 women diagnosed with endometrial cancer using immunohistochemistry for TP53 and MMR proteins on a tissue microarray, as well as Sanger sequencing for POLE mutations. These results, combined with clinicopathologic data, allowed the patients to be risk grouped using both the new 2021 molecular/clinicopathologic parameters and the prior 2016 clinicopathologic system. RESULTS: The application of the 2021 molecular markers shows Kaplan-Meier curves with a significant difference between the groups for all survival. Molecular classification under the 2021 guidelines revealed a total of 39 patients (39/594, 7%) with a change in risk group in relation to the 2016 classification system: the shift was alone due to either P53abn or POLEmut molecular marker. In order to ensure correct 2021 molecular risk classification, not all patients with endometrial cancer need a molecular diagnostic: 433 (72.9%) cases would need to be analyzed by TP53 IHC, only 46 (7.7%) by MMR IHC and 286 (48.1%) POLE sequencing reactions. CONCLUSION: Application of the 2021 molecular risk groups is feasible and shows significant differences in survival. IHC for TP53 and MMR and applying POLE sequencing is only needed in selected cases and leads to shifting risk groups both upward and downward for a sizeable number of patients. It is possible to significantly reduce the number of analyses required to implement the classification if resources are limited.
引用
- Imboden S, Nastic D, Ghaderi M, et al. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer. Gynecol Oncol. 2021. PMID: 34127276. doi:10.1016/j.ygyno.2021.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。